Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Design Consideration01:22

Design Consideration

467
Designing a structure involves a series of considerations, primarily the material's ultimate strength, calculated through tests that measure changes under increased force until the material reaches its breaking point or limit. The ultimate load, where the material breaks, is divided by its original cross-sectional area, resulting in the ultimate normal stress or strength. The ultimate shearing stress is another significant factor taken into account.
The factor of safety is another key...
467
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Design of Prismatic Beams for Bending01:23

Design of Prismatic Beams for Bending

555
The design of prismatic beams, structural elements with a uniform cross-section, focuses on ensuring safety and structural integrity under load. The design process begins by determining the allowable stress, either from material properties tables, or by dividing the material's ultimate strength by a safety factor. This safety factor is essential for accommodating uncertainties, and varies depending on the material—timber, steel, or concrete—with each having unique strength and...
555
Quality Assurance01:19

Quality Assurance

879
Quality assurance is the overarching term used to describe the activities employed to ensure the proper performance of a system. These activities can be classified into three categories: quality control, quality assessment, and internal corrective measures. Typically, these activities work cyclically: quality control is performed before and during the analysis, while quality assessment occurs during and after the investigation. Internal corrective measures are implemented based on the findings...
879
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

138
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
138
Drug Regulation01:25

Drug Regulation

2.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling.

Cancer causes & control : CCC·2026
Same author

Content validity, face validity and comprehensiveness of generic quality-of-life measures in adults and children with rare genetic conditions and their carers: a think aloud qualitative study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

A Large Language Model for Extracting Post-marketing Adverse Drug Events from Clinical Notes in the Electronic Health Record.

Drug safety·2026
Same author

Implementing a Climate Health Education Curriculum for Emergency Medicine Trainees and Faculty.

The western journal of emergency medicine·2026

Related Experiment Video

Updated: Dec 18, 2025

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle
14:57

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle

Published on: January 30, 2019

14.3K

A Framework for Safety Evaluation Throughout the Product Development Life-Cycle.

Greg Ball1, Tjark Reblin2, James Buchanan3

  • 1Clinical Safety Statistics, Merck & Co, Inc, RY 34-A318, 126 E Lincoln Ave, Rahway, NJ, 07065-4607, USA. Greg.Ball@Merck.com.

Therapeutic Innovation & Regulatory Science
|June 20, 2020
PubMed
Summary

This study introduces a proactive, integrated approach to medicine safety evaluation, utilizing diverse data sources from early development through post-marketing. This method enhances understanding of drug benefit-risk profiles for better patient safety and regulatory compliance.

Keywords:
Aggregate safety assessmentFrameworkInterdisciplinary safety evaluationIterative processLearning and decision-making

More Related Videos

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
04:55

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System

Published on: November 22, 2016

7.0K
Experimental Protocol to Investigate Particle Aerosolization of a Product Under Abrasion and Under Environmental Weathering
07:47

Experimental Protocol to Investigate Particle Aerosolization of a Product Under Abrasion and Under Environmental Weathering

Published on: September 16, 2016

7.7K

Related Experiment Videos

Last Updated: Dec 18, 2025

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle
14:57

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle

Published on: January 30, 2019

14.3K
Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
04:55

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System

Published on: November 22, 2016

7.0K
Experimental Protocol to Investigate Particle Aerosolization of a Product Under Abrasion and Under Environmental Weathering
07:47

Experimental Protocol to Investigate Particle Aerosolization of a Product Under Abrasion and Under Environmental Weathering

Published on: September 16, 2016

7.7K

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Regulatory Science
  • Data Science in Healthcare

Background:

  • Traditional medicine safety evaluation relied on reactive analysis of clinical trials and spontaneous reports.
  • A shift towards proactive, integrated safety assessments is emerging in pharmaceutical development.
  • Cross-functional teams are increasingly focusing on early anticipation of benefit-risk profiles.

Purpose of the Study:

  • To propose and describe a proactive, integrated approach to evaluating the safety profile of medicines.
  • To highlight the use of diverse data sources for a comprehensive understanding of drug safety.
  • To emphasize the importance of continuous learning and multidisciplinary collaboration in risk management.

Main Methods:

  • Integration of safety data from multiple sources: preclinical, clinical, spontaneous adverse events, epidemiological, real-world, registry, and social media data.
  • Application of blended qualitative and quantitative evaluation techniques for data integration.
  • Implementation of a collaborative, multidisciplinary approach with continuous learning and decision-making.

Main Results:

  • The proposed approach facilitates a strategic evolution in understanding drug safety profiles.
  • Integrated program-level safety data assessments provide a comprehensive view.
  • Multifaceted and iterative evaluations, starting early in development, enhance risk management.

Conclusions:

  • This proactive, integrated safety evaluation method satisfies regulatory requirements.
  • It leads to a better understanding of a drug's safety profile for healthcare systems and patients.
  • Continuous learning and multidisciplinary collaboration are key to effective drug safety management throughout the product lifecycle.